PMID- 25276283
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141003
LR  - 20220310
IS  - 1948-5182 (Print)
IS  - 1948-5182 (Electronic)
VI  - 6
IP  - 9
DP  - 2014 Sep 27
TI  - Skin toxicity predicts efficacy to sorafenib in patients with advanced 
      hepatocellular carcinoma.
PG  - 670-6
LID - 10.4254/wjh.v6.i9.670 [doi]
AB  - AIM: To study the relationship between adverse events (AEs), efficacy, and 
      nursing intervention for sorafenib therapy in patients with hepatocellular 
      carcinoma (HCC). METHODS: We enrolled 37 consecutive patients with advanced HCC 
      who received sorafenib therapy. Relationships among baseline characteristics as 
      well as AE occurrence and tumor response, overall survival (OS), and treatment 
      duration were analyzed. The nursing intervention program consisted of education 
      regarding self-monitoring and AEs management, and telephone follow-up was 
      provided once in 1-2 wk. RESULTS: A total of 37 patients were enrolled in the 
      study, comprising 30 males (81%) with a median age of 71 years. The disease 
      control rate at 3 mo was 41%, and the median OS and treatment duration were 259 
      and 108 d, respectively. Nursing intervention was given to 24 patients (65%). 
      Every patient exhibited some kinds of AEs, but no patients experienced G4 AEs. 
      Frequently observed AEs > G2 included anorexia (57%), skin toxicity (57%), and 
      fatigue (54%). Factors significantly associated with longer OS in multivariate 
      analysis demonstrated that age </= 70 years, presence of > G2 skin toxicity, and 
      absence of > G2 hypoalbuminemia. The disease control rate in patients with > G2 
      skin toxicity was 13/20 (65%), which was significantly higher compared with that 
      in patients with no or G1 skin toxicity. Multivariate analysis revealed that 
      nursing intervention and > G2 skin toxicity were independent significant 
      predictors for longer treatment duration. CONCLUSION: Skin toxicity was 
      associated with favorable outcomes with sorafenib therapy for advanced HCC. 
      Nursing intervention contributed to better adherence, which may improve the 
      efficacy of sorafenib.
FAU - Shomura, Masako
AU  - Shomura M
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Kagawa, Tatehiro
AU  - Kagawa T
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Shiraishi, Koichi
AU  - Shiraishi K
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Hirose, Shunji
AU  - Hirose S
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Arase, Yoshitaka
AU  - Arase Y
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Koizumi, Jun
AU  - Koizumi J
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
FAU - Mine, Tetsuya
AU  - Mine T
AD  - Masako Shomura, Department of Nursing, Tokai University School of Health 
      Sciences, Isehara, Kanagawa 2591193, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC4179146
OTO - NOTNLM
OT  - Drug toxicity
OT  - Hepatocellular carcinoma
OT  - Molecular targeted therapy
OT  - Nursing intervention
OT  - Surrogate marker
EDAT- 2014/10/03 06:00
MHDA- 2014/10/03 06:01
PMCR- 2014/09/27
CRDT- 2014/10/03 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/07/16 00:00 [revised]
PHST- 2014/08/27 00:00 [accepted]
PHST- 2014/10/03 06:00 [entrez]
PHST- 2014/10/03 06:00 [pubmed]
PHST- 2014/10/03 06:01 [medline]
PHST- 2014/09/27 00:00 [pmc-release]
AID - 10.4254/wjh.v6.i9.670 [doi]
PST - ppublish
SO  - World J Hepatol. 2014 Sep 27;6(9):670-6. doi: 10.4254/wjh.v6.i9.670.